OrganOx and eGenesis Announce Exclusive Clinical Co-Development Agreement for Treatment of Patients with Liver Failure in the Acute Setting OrganOx and eGenesis Announce Exclusive Clinical Co-Development Agreement for Treatment of Patients with Liver Failure in the Acute Setting

Appointment of Stephen M. Deitsch as new Chief Financial Officer OrganOx Appoints Stephen M. Deitsch, an experienced medtech finance leader with proven track record with IPOs, as new Chief Financial Officer.

OrganOx Raises £25 Million in Growth Round Led by Lauxera Capital Partners OXFORD, United Kingdom, July 17, 2023 (GLOBE NEWSWIRE) -- OrganOx Ltd (“OrganOx” or the “Company”), a world-leading medical technology company committed to making every donated organ count with...

Medical Perfusion Technology Market to Outstrip $962.60 Million by 2027 Growing Sturdy at 4.1% CAGR - COVID-19 Impact and Global Analysis by TheInsightPartners.com Pune, India., June 22, 2021 (GLOBE NEWSWIRE) -- Medical Perfusion Technology Market: Key InsightsAccording to our new research study on “Medical Perfusion Technology Market to 2027 – Global Analysis...